AstraZeneca Pharmaceuticals LP
NEWS
On Sunday, Reuters reported the U.K. pharma giant sold off its 7.7% stake in the company for more than $1 billion.
After announcing a successful primary endpoint in November, AstraZeneca and Amgen presented the full data on their severe asthma antibody candidate on Friday.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 23, 2021.
AstraZeneca will voluntarily withdraw the use of its checkpoint inhibitor Imfinzi (durvalumab) as a treatment for bladder cancer in the United States following a failure to meet endpoints in a post-approval clinical study.
AstraZeneca Chief Executive Officer Pascal Soriot is seeing a significant return on the fruits of his company’s labor in 2020. Soriot’s annual compensation jumped a bit from the previous year to $21.4 million.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 16, 2021.
The WHO’s Emergency Use Listing (EUL), a prerequisite for COVAX Facility vaccine supply, evaluates the safety, quality, and efficacy of the COVID-19 vaccines. As such, today’s approval allows the vaccine to be used by agencies and NGOs around the world.
In the waning weeks of the fourth quarter of the 2020 fiscal year, AstraZeneca terminated several clinical programs, including some oncology and heart-related studies, as well as one COVID-19 related trial.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 9, 2021.
JOBS
IN THE PRESS